412-246-6111

 

Treatment of Insomnia & Depression (TRIAD)

 

 

Home     Depression     Bipolar Disorder     Cognitive Therapy     Research     Staff     Contact    TV ADs

 

 

Current Studies

Depression:

* Insomnia & Depression

* Transcranial Magnetic Stimulation (TMS)

* New Medication Trial (ROCHE)

* Buprenorphine for TRD

* New Medication Trial (Shire)

Assessment Only:

* Emotion/Physiology

Bipolar Disorder:

* Quetiapine vs. Lithium

 
Purpose

The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.

Detailed Description:

Participants with major depressive disorder and insomnia who meet all study criteria will receive state-of-the-art antidepressant medications and one of two insomnia therapies. The specific therapy for insomnia will be determined by chance (like a flip of a coin), with an equal chance to receive either cognitive-behavioral therapy for insomnia or desensitization psychotherapy for insomnia. The study physician will select an initial antidepressant medication from a list of three possible medications . If that medication is not helpful, another medication may be tried after 8 weeks or in the event of severe side effects.

Eligibility

 
Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

For further information please call 412-246-6111, click here to email us, or visit one of the following websites: http://www.triadproject.org/ or clinicaltrials.gov.

 

 
 

If you have any questions or comments about this web site, please contact the webmaster.  For all other questions please click the contact link.

This website was last updated 06/14/2012.

© 2005 Mood Disorders Treatment and Research Program (MDTRP), Department of Psychiatry, Western Psychiatric Institute and Clinic (WPIC), UPMC Health System